Bicycle Therapeutics Ownership | Who Owns Bicycle Therapeutics?
Bicycle Therapeutics Ownership Summary
Bicycle Therapeutics is owned by 19.05% institutional investors, 1.40% insiders, and 79.56% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 15.72% of BCYC shares. T. Rowe Price Health Sciences is the top mutual fund, with 1.56% of its assets in Bicycle Therapeutics shares.
BCYC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Bicycle Therapeutics | 19.05% | 1.40% | 79.56% |
| Sector | Healthcare Stocks | 232.51% | 10.72% | -143.23% |
| Industry | Biotech Stocks | 384.56% | 10.58% | -295.14% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Baker bros. advisors lp | 10.89M | 15.72% | $84.25M |
| Fcpm iii services b.v. | 3.45M | 4.99% | $26.72M |
| Westfield capital management co lp | 3.02M | 4.35% | $21.35M |
| Armistice capital | 2.98M | 4.30% | $23.05M |
| Siren | 2.01M | 2.91% | $15.58M |
| Acadian asset management | 1.67M | 2.41% | $11.81M |
| Gsk | 1.53M | 2.21% | $10.83M |
| Long focus capital management | 1.42M | 2.05% | $10.98M |
| Price t rowe associates inc /md/ | 1.38M | 2.00% | $10.72M |
| Candriam s.c.a. | 1.17M | 1.69% | $9.07M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Fcpm iii services b.v. | 3.45M | 5.34% | $26.72M |
| Aquilo capital management | 171.69K | 2.61% | $1.46M |
| Gsk | 1.53M | 1.36% | $10.83M |
| Birchview capital, lp | 154.00K | 0.90% | $1.19M |
| Nan fung group | 68.94K | 0.90% | $533.62K |
| Rangeley capital | 130.00K | 0.87% | $1.01M |
| Siren | 2.01M | 0.61% | $15.58M |
| Baker bros. advisors lp | 10.89M | 0.61% | $84.25M |
| Monimus capital management, lp | 85.22K | 0.41% | $659.63K |
| Long focus capital management | 1.42M | 0.36% | $10.98M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Gsk | 1.53M | 1.36% | 1.53M |
| Acadian asset management | 1.67M | 0.02% | 356.70K |
| Millennium management | 453.43K | 0.00% | 276.67K |
| Silvercrest asset management group | 476.98K | 0.02% | 211.28K |
| Armistice capital | 2.98M | 0.34% | 178.00K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | - | - | -3.25M |
| Point72 asset management | 430.90K | 0.01% | -1.34M |
| Deep track capital, lp | - | - | -1.20M |
| Ra capital management | - | - | -1.09M |
| Bnp paribas asset management | - | - | -1.04M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Gsk | 1.53M | 1.36% | 1.53M | $10.83M |
| Birchview capital, lp | 154.00K | 0.90% | 154.00K | $1.19M |
| Marex group | 78.41K | 0.00% | 78.41K | $555.11K |
| Fox run management | 19.77K | 0.02% | 19.77K | $139.98K |
| Vanguard personalized indexing management | 12.95K | 0.00% | 12.95K | $100.26K |
Sold Out
| Holder | Change |
|---|---|
| Zurcher kantonalbank (zurich cantonalbank) | -4.00 |
| Northwestern mutual wealth management | -5.00 |
| Mather group, llc. | -5.00 |
| Steward partners investment advisory | -10.00 |
| Ronald blue trust | -11.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 68 | -33.98% | 13,199,592 | -64.23% | 19 | 0.67% | 32 | -34.69% | 19 | -17.39% |
| Sep 30, 2025 | 94 | -16.07% | 32,600,347 | -18.41% | 47 | 1.41% | 46 | -26.98% | 20 | -4.76% |
| Jun 30, 2025 | 115 | 18.56% | 41,177,900 | -1.34% | 59 | 1.63% | 66 | 53.49% | 21 | -30.00% |
| Mar 31, 2025 | 1 | -99.00% | 68,943 | -99.84% | - | 0.00% | - | -100.00% | - | -100.00% |
| Dec 31, 2024 | 99 | -10.00% | 41,889,682 | 3.58% | 60 | 1.77% | 44 | -16.98% | 36 | 12.50% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Health Sciences | 1.08M | 1.56% | -12.15K |
| Harbor Small Cap Growth Instl | 970.00K | 1.40% | -30.82K |
| Westfield Capital Mgt Co Sm-Cap Gr Eq | 970.00K | 1.40% | -30.82K |
| Candriam Eqs L Biotech C USD Cap | 805.24K | 1.16% | - |
| BNP Paribas Health Cr Innovtr Cl Cap | 567.98K | 0.82% | -563.00 |
| Principal SmallCap R5 | 538.99K | 0.78% | 200.69K |
| Candriam Global Equities Oncology | 492.11K | 0.71% | 125.18K |
| BNP Paribas US Small Cap ClassicC | 476.45K | 0.69% | 1.24K |
| BNP Paribas US Small Cap Classic R | 468.06K | 0.68% | -9.43K |
| Belfius Equities Cure C Cap | 367.15K | 0.53% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jan 02, 2026 | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | Sell | $8.96K |
| Jan 05, 2026 | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | Sell | $7.19K |
| Jan 05, 2026 | Skynner Michael | CHIEF TECHNOLOGY OFFICER | Sell | $21.10K |
| Jan 02, 2026 | Skynner Michael | CHIEF TECHNOLOGY OFFICER | Sell | $20.71K |
| Jan 02, 2026 | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | Sell | $19.22K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 13 |
| 2025 Q4 | - | 13 |
| 2025 Q3 | - | 11 |
| 2025 Q2 | - | 11 |
| 2025 Q1 | - | 15 |
BCYC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools